125 results
Page 4 of 7
8-K
EX-99.1
0e082dsa7xgsoxa6
28 Mar 19
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
6:05am
8-K
EX-99.1
ed4 nb3rxw84k2
22 Mar 19
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
4:17pm
8-K/A
2wn5xa
6 Mar 19
Entry into a Material Definitive Agreement
5:02pm
8-K/A
EX-10.1
a63zgwjc5syr
6 Mar 19
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-10.1
8kxy7ay2xlqyfay
4 Mar 19
Entry into a Material Definitive Agreement
7:05am
424B5
e47 o9eo6um
19 Feb 19
Prospectus supplement for primary offering
8:39am
8-K
EX-99.2
y1ana3tbmb
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
8wkw1c
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
r87amoc
7 Jan 19
Other Events
7:01am
8-K
EX-10.1
dd5up1us 6oel5gm
4 Jan 19
Entry into a Material Definitive Agreement
4:23pm
8-K
EX-99.1
u9o012 dx0
10 Dec 18
Other Events
2:07pm
8-K
EX-99.1
j7rg l2ub3jqqcz
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.2
8dnxplzj
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.1
mekmhoi 5h
9 Oct 18
Recro Pharma Announces PDUFA Date for IV Meloxicam
6:07am
8-K
EX-99.1
tbqu7sex
1 Oct 18
Recro Announces Expansion of CDMO Service Capabilities
12:00am